passages: 1560
passages: document
passages: To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud 's phenomenon in South Korea ; Korean Raynaud study ( KOARA study ) . This study examined the efficacy and safety of nifedipine sustained release ( nifedipine SR ) compared with Ginkgo biloba extract as treatment for primary Raynaud 's phenomenon ( RP ) in Korea . Primary RP were screened and assigned to either the nifedipine SR group ( Group N ) or the Ginkgo biloba extract group ( Group G ) in the ratio of 2:1 . After a run-in period of 2 weeks , patients received treatment for 8 weeks . We observed the percent improvement of the RP attack rate between before and after the 8-week treatment . Ninety-three subjects were randomly assigned . The percent improvement in Group N was 50.1 % at 8 weeks after treatment , while it was 31.0 % in Group G ( p = 0.03 ) . No serious adverse events occurred , and almost adverse events were mild and improved without specific treatment . nifedipine SR was more effective than Ginkgo biloba extract for treatment of primary RP in Korean patients . Both drugs were tolerable with primary RP patients .
entities: 1561
entities: Intervention_Pharmacological
entities: nifedipine sustained release
entities: 1562
entities: Intervention_Pharmacological
entities: Ginkgo biloba extract
entities: 1563
entities: Intervention_Pharmacological
entities: nifedipine sustained release ( nifedipine SR )
entities: 1564
entities: Intervention_Pharmacological
entities: Ginkgo biloba extract
entities: 1565
entities: Intervention_Pharmacological
entities: nifedipine SR
entities: 1566
entities: Intervention_Pharmacological
entities: Ginkgo biloba extract
entities: 1567
entities: Intervention_Pharmacological
entities: nifedipine SR
entities: 1568
entities: Intervention_Pharmacological
entities: Ginkgo biloba extract
entities: 1569
entities: Outcome_Other
entities: efficacy
entities: 1570
entities: Outcome_Other
entities: safety
entities: 1571
entities: Outcome_Other
entities: efficacy
entities: 1572
entities: Outcome_Other
entities: safety
entities: 1573
entities: Outcome_Physical
entities: percent improvement of the RP attack rate
entities: 1574
entities: Outcome_Adverse-effects
entities: serious adverse events
entities: 1575
entities: Outcome_Adverse-effects
entities: adverse events
entities: 1576
entities: Outcome_Other
entities: effective
entities: 1577
entities: Outcome_Other
entities: tolerable
entities: 1578
entities: Participant_Condition
entities: patients with primary Raynaud 's phenomenon in South Korea ;
entities: 1579
entities: Participant_Sample-size
entities: Ninety-three subjects
entities: 1580
entities: Participant_Condition
entities: Korean patients .
entities: 1581
entities: Participant_Condition
entities: RP patients .